Access Pharmaceuticals to present two oncology posters at CPR Conference ACCESS PHARMACEUTICALS, INC. , a biopharmaceutical firm leveraging its proprietary drug-delivery platforms to build up treatments in areas of oncology, cancers supportive diabetes and treatment, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Meeting at the Austin Convention Middle in Austin, TX. Related StoriesLilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapiesNew guidance statement on palliative treatment to be presented at 2015 Palliative Treatment in Oncology SymposiumResearchers determine new target for novel immune-oncology treatments We are pleased to be one of them year’s Innovations in Cancer Prevention and Research Conference as the team’s analysis in both applications support a substantial opportunity in treating several cancers, said David Nowotnik, Senior VP of Research and Development, Gain access to Pharmaceuticals, Inc.Results A total of 4628 patients were enrolled, of whom 2301 were randomly assigned to receive dronedarone and 2327 to get placebo . The two groups were well matched regarding baseline characteristics . General, the mean age group was 71.6 years, and 46.9 percent of participants were female. Twenty-five % of patients experienced atrial fibrillation at randomization. The predominant underlying cardiovascular disease was hypertension, and there was evidence of structural heart disease in the majority of patients for whom the info were available.11 The still left ventricular ejection fraction was quantified in 4544 sufferers, of whom 179 and 540 acquired an ejection fraction of less than 35 percent and less than 45 percent, respectively.